Skip to search formSkip to main contentSkip to account menu

Anti-CEA BiTE Monoclonal Antibody MEDI-565, Human

Known as: MEDI-565 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
TPS3097 Background: The bispecific CD19-directed CD3 T-cell engager (BiTE(R)) blinatumomab was recently approved by FDA as single… 
2012
2012
MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTE®) antibody in development for the treatment of patients with… 
2012
2012
Colorectal cancer (CRC) cells can harbor somatic mutations with strong impact on cancer cell signaling that limit the… 
2011
2011
the changing environment of monoclonal antibody (mAb) development is impacting on the cost of drug development and the use of… 
2010
2010
MEDI-565 (MT111) is a novel bispecific single-chain antibody of the BiTE (Bi-specific T-cell engager) class that transiently… 
2010
2010
MEDI-565 (MT111) is a novel bispecific single-chain antibody of the BiTE (Bispecific T cell engager) class that transiently links… 
2010
2010
Carcinoembryonic antigen (CEA; CD66e, CEACAM5) is a well-characterized tumor-associated antigen that is frequently and uniformly… 
Highly Cited
2009
Highly Cited
2009
Background:Novel technologies to redirect T-cell killing against cancer cells are emerging. We hypothesised that metastatic human…